If you or a loved one has been diagnosed with Alzheimer’s disease, you or they may be eligible to participate in a clinical research study evaluating ATH-1017, a new investigational drug, to see if it is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function.
Clinical Research Professionals in Chesterfield is enrolling adults ages 55 to 85 who have been diagnosed with Alzheimer’s disease to take part in this study.
Study participation and study drug are free to all participants and you may receive a stipend up to $702 to compensate for time and effort for study participation including meals, travel, etc.